Among these patients, 45.2% achieved a dose of 1 mg (injectable), and 14.2% reached 14 mg (oral) [1]
Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study
doi: 10.2337/diab.42.5.658 95 ReedJBainSKanamarlapudiV
ArGLP-1 also reduced total mortality (HR 0.88, 95% CI 0.820.94, p = 0.0001) and hospital admission due to heart failure (HR 0.89, 95% CI 0.820.98, p = 0.013), all without increasing the risk of severe hypoglycemia, pancreatic problems or retinopathy.87 A recent post hoc analysis of CVOT with semaglutide has shown a gain in time free of cardiovascular disease of 1.7 years in those patients with CKD vs
Employer coverage - Check with your employer to learn about employer sponsored health plan options, rules and deadlines